Enliven Therapeutics (US:ELVN) — Company Overview, News & Financial Data

Enliven Therapeutics logo
ELVNEnliven Therapeutics
Trade ELVN now
Enliven Therapeutics primary media

About Enliven Therapeutics

Enliven Therapeutics (NASDAQ:ELVN) focuses on innovative cancer treatments, emphasizing personalized medicine to optimize patient outcomes. At the core of its operations, Enliven Therapeutics merges cutting-edge research with advanced technology to develop therapies that target specific cancer pathways. The company's projects range from early-stage research to clinical trials, always aiming to bring novel solutions to the forefront of oncology care. Their objectives include revolutionizing cancer treatment through the discovery, development, and commercialization of therapies that offer improved efficacy and safety, ultimately striving to enhance the quality of life for patients battling cancer.

What is ELVN known for?

Snapshot

Public US
Ownership
2016
Year founded
13
Employees
Colorado, United States
Head office
Loading Map...

Operations

All Locations
United States

Products and/or services of Enliven Therapeutics

  • Development of targeted cancer therapies focusing on genetically defined patient populations for precision medicine.
  • Advancement of novel inhibitors for the treatment of lung cancer and other solid tumors.
  • Research on immune system modulators to enhance the efficacy of existing cancer treatments.
  • Collaboration with biotech and pharmaceutical companies to accelerate the development and commercialization of promising cancer therapies.
  • Investment in cutting-edge technology to improve the delivery and specificity of oncology drugs.
  • Initiation of clinical trials for new molecules with potential application across a range of cancers.

Enliven Therapeutics executive team

  • Mr. Samuel S. Kintz M.B.A.Co-Founder & Head of Pipeline
  • Dr. Joseph P. Lyssikatos Ph.D.Co-Founder & Chief Scientific Officer
  • Dr. Helen Louise Collins M.D.Chief Medical Officer
  • Mr. Richard A. FairCEO, President & Director
  • Mr. Anish Patel Pharm.D.Co-Founder & COO
  • Mr. Benjamin HohlCFO & Head of Corporate Development
  • Dr. Galya D. Blachman Esq., Ph.D.Chief Legal Officer & Head of Business Development

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.